The Impact of Appropriateness of Empirical Antibiotic in Hospitalized Pneumonia Patients on Clinical Outcomes and Length of Stay
DOI:
https://doi.org/10.59188/eduvest.v4i11.1450Keywords:
Empirical Antibiotic, Pneumonia, Clinical Outcome, Length of StayAbstract
Pneumonia is the leading cause of morbidity and mortality in adults worldwide. The incidence of pneumonia is still very high in Indonesia. The main standard therapy for pneumonia is empirical antibiotic administration. The purpose of this study was to determine whether there was an impact of the appropriateness of empirical antibiotics therapy on clinical outcomes and length of stay of non-ICU pneumonia patients at X Hospital in Jakarta. This study used a retrospective cohort design to determine the appropriateness of empirical antibiotics use in non-ICU pneumonia patients. The samples taken are all non-ICU pneumonia patients during the period January 2022 – December 2023 who met the inclusion criteria. Data analysis was carried out descriptively for patient characteristics, drug use profile, and the appropriateness of empirical antibiotic. A chi-square test was used to determine the impact of appropriateness of empirical antibiotics on clinical outcomes and length of stay. The appropriateness of empirical antibiotics obtained 59,5% (173 regimens) met category 0 (appropriate), and 40,5% (118 regimens) met category I-VI (inappropriate). Based on the results, there is an impact of the appropriateness of empirical antibiotics on clinical outcomes (P = 0,000; RR =1,916; 95% CI = 1,558 – 2,357), and impact of of the appropriateness of empirical antibiotics on length of stay (P = 0,002; RR =1,410; 95% CI = 1,126 – 1,765). The analysis's results showed that the impact of appropriateness of empirical antibiotic on clinical outcomes and length of stay of non-ICU inpatients with pneumonia at X Hospital in Jakarta.
References
Albrich, W. C., Rassouli, F., Waldeck, F., Berger, C., & Baty, F. (2019). Influence of Older Age and Other Risk Factors on Pneumonia Hospitalization in Switzerland in the Pneumococcal Vaccine Era. Frontiers in Medicine, 6(December), 1–10. https://doi.org/10.3389/fmed.2019.00286
Aljufri, A. Q., Yasin, N. M., & Wahyono, D. (2021). Rasionalitas Terapi Antibiotik Empiris Pada Pasien Pneumonia di Instalasi Rawat Inap RSUP Dr. Kariadi Semarang. Majalah Farmaseutik, 17(1), 89. https://doi.org/10.22146/farmaseutik.v17i1.53702
Ariyanti, D., Sauriasari, R., & Yunir, E. (2022). Evaluation of Current Practice of Antibiotic Use and Clinical Outcomes of Community-Acquired Pneumonia Patients with Type 2 Diabetes Mellitus at Dr. Cipto Mangunkusumo Hospital, Jakarta, Indonesia. Indonesian Journal of Pharmacy, 33(4), 583–591. https://doi.org/10.22146/ijp.3572
Baddour, L. M., Yu, V. L., Klugman, K. P., Feldman, C., Ortqvist, A., Rello, J., Morris, A. J., Luna, C. M., Snydman, D. R., Wen, C. K., Chedid, M. B. F., Hui, D. S., Andremont, A., Chiou, C. C. C., Mosquera, R., De Mier, C., Famiglietti, A., Vay, C., Gentile, J., … Rihs, J. D. (2004). Combination Antibiotic Therapy Lowers Mortality among Severely III Patients with Pneumococcal Bacteremia. American Journal of Respiratory and Critical Care Medicine, 170(4), 440–444. https://doi.org/10.1164/rccm.200311-1578OC
Bosch, C. M. A. Van Den, Hulscher, M. E. J. L., Akkermans, R. P., Wille, J., Geerlings, S. E., & Prins, J. M. (2017). Appropriate antibiotic use reduces length of hospital stay. December 2016, 923–932. https://doi.org/10.1093/jac/dkw469
Charlson, et al. (1987). A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. Journal of Chronic Diseases.
Çilli, A., Sayiner, A., Çelenk, B., Şakar Coşkun, A., Kilinç, O., Hazar, A., Aktaş Samur, A., Taşbakan, S., Waterer, G. W., Havlucu, Y., Kiliç, Ö., Tokgöz, F., & Bilge, U. (2018). Antibiotic treatment outcomes in community-acquired pneumonia. Turkish Journal of Medical Sciences, 48(4), 730–736. https://doi.org/10.3906/sag-1709-144
Davey, P. G. (2008). Appropriate vs. inappropriate antimicrobial therapy. Clinical Microbiology and Infection, 14(SUPPL. 3), 15–21. https://doi.org/10.1111/j.1469-0691.2008.01959.x
Elshenawy, R., Umaru, N., & Aslanpour, Z. (2024). Shorter and Longer Antibiotic Durations for Respiratory Infections: To Fight Antimicrobial Resistance—A Retrospective Cross-Sectional Study in a Secondary Care Setting in the UK. Pharmaceuticals, 17(3). https://doi.org/10.3390/ph17030339
Fagerli, K., Ulziibayar, M., Suuri, B., Luvsantseren, D., Narangerel, D., Batsaikhan, P., Tsolmon, B., Gessner, B. D., Dunne, E. M., Grobler, A. C., Nguyen, C. D., Mungun, T., Mulholland, E. K., & Mollendorf, C. Von. (2023). Articles Epidemiology of pneumonia in hospitalized adults ≥ 18 years old in four districts of Ulaanbaatar ,. The Lancet Regional Health - Western Pacific, 30, 100591. https://doi.org/10.1016/j.lanwpc.2022.100591
Fatia, ;, Supadmi Woro, Perwitasari Dyah Aryani, & Yuniarti Endang. (2021). Hubungan Ketepatan Peresepan Antibiotik dengan Metode Gyssens dengan Perbaikan Klinis Pasien Rawat Inap Pneumonia Komunitas. Jurnal Ilmu Kefarmasian Indonesia, 19(1), 30–38.
Ferrara, A. M. (2007). A brief review of moxifloxacin in the treatment of elderly patients with community-acquired pneumonia (CAP). Clinical Interventions in Aging, 2(2), 179–187.
Gunduz, C., Taşbakan, M. S., Sayiner, A., Çilli, A., Kilinç, O., & Şakar Coşkun, A. (2016). Factors affecting treatment success in community-acquired pneumonia. Turkish Journal of Medical Sciences, 46(5), 1469–1474. https://doi.org/10.3906/sag-1502-87
Gyssens, I. C. (2001). Quality of antimicrobial drug prescription in hospital. Clinical Microbiology and Infection, 7(SUPPL. 6), 12–15. https://doi.org/10.1046/j.1469-0691.2001.00079.x
Hardiana, I., Ratih Laksmitawati Dian, Ramadaniati Hesty utami, & sutarno. (2021). Evaluasi Penggunaan Antibiotika Pada Pasien Pneumonia Komunitas Di Instalasi Rawat Inap Rspad Gatot Subroto. Majalah Farmasi Dan Farmakologi, 25(1), 1–6. https://doi.org/10.20956/mff.v25i1.11555
Jacobs, M. R. (2001). Optimisation of antimicrobial therapy using pharmacokinetic and pharmacodynamic parameters. Clinical Microbiology and Infection, 7(11), 589–596. https://doi.org/10.1046/j.1198-743X.2001.00295.x
Kamila, R. S., Rochmanti, M., & Bakhtiar, A. (2021). Appropriate antibiotic use for community-acquired pneumonia in inpatient settings and its impact on 30-days readmission and mortality rate. Indian Journal of Forensic Medicine and Toxicology, 15(1), 2765–2772. https://doi.org/10.37506/ijfmt.v15i1.13817
Kemenkes. (2015). Progran Pengendalian Resistensi Antimikroba. Peraturan Menteri Kesehatan Republik Indonesia Nomor 8, 151, 10–17.
Kemenkes. (2018). Riskendas 2018. Laporan Nasional Riskesndas 2018, 44(8), 181–222.
Kemenkes. (2021a). Pedoman Nasional Pelayanan Kedokteran Tata Laksana Pneumonia. Kementerian Kesehatan RI, 1–85.
Kemenkes. (2021b). Pedoman Penggunaan Antibiotik. Permenkes RI, 1–97.
Kuscu, F., Ulu, A., Inal, A. S., Suntur, B. M., Aydemir, H., Gul, S., Ecemis, K., Komur, S., Kurtaran, B., Kuscu, O. O., & Tasova, Y. (2018). Potential drug–drug interactions with antimicrobials in hospitalized patients: A multicenter point-prevalence study. Medical Science Monitor, 24, 4240–4247. https://doi.org/10.12659/MSM.908589
Lüthi-Corridori, G., Boesing, M., Roth, A., Giezendanner, S., Leuppi-Taegtmeyer, A. B., Schuetz, P., & Leuppi, J. D. (2023). Predictors of Length of Stay, Rehospitalization and Mortality in Community-Acquired Pneumonia Patients: A Retrospective Cohort Study. Journal of Clinical Medicine, 12(17). https://doi.org/10.3390/jcm12175601
Manohar, P., Loh, B., Athira, S., Nachimuthu, R., Hua, X., Welburn, S. C., & Leptihn, S. (2020). Secondary Bacterial Infections During Pulmonary Viral Disease: Phage Therapeutics as Alternatives to Antibiotics? Frontiers in Microbiology, 11(June), 1–11. https://doi.org/10.3389/fmicb.2020.01434
Meriyani, H., Sanjaya, D. A., Juanita, R. A., & Siada, N. B. (2024). Kualitas Penggunaan Antibiotik pada Pasien Community-Acquired Pneumonia di Salah Satu Rumah Sakit di Bali. Jurnal Ilmiah Medicamento, 10(1), 35–42. https://doi.org/10.36733/medicamento.v10i1.7592
Metlay, J. P., Waterer, G. W., Long, A. C., Anzueto, A., Brozek, J., Crothers, K., Cooley, L. A., Dean, N. C., Fine, M. J., Flanders, S. A., Griffin, M. R., Metersky, M. L., Musher, D. M., Restrepo, M. I., & Whitney, C. G. (2019). Diagnosis and treatment of adults with community-acquired pneumonia. American Journal of Respiratory and Critical Care Medicine, 200(7), E45–E67. https://doi.org/10.1164/rccm.201908-1581ST
Mujiyanti, M., Perwitasari, D. A., Darmawan, E., & Risdiana, I. (2021). Evaluasi Kesesuaian Pemberian Antibiotik Empiris Terhadap Antibiogram dan Luaran Klinis pada Pasien Pneumonia Dewasa. Jurnal Ilmu Kefarmasian Indonesia, 19(1), 102. https://doi.org/10.35814/jifi.v19i1.920
Munarsih, F. C., Natadidjaja, R. I., & Syamsudin, S. (2018). Pengaruh Pemberian Antibiotik berdasar Panduan terhadap Lama Tinggal pada Pasien Pneumonia Komunitas di Rumah Sakit. Jurnal Penyakit Dalam Indonesia, 5(3), 141. https://doi.org/10.7454/jpdi.v5i3.195
Nguyen, M. T. N., Saito, N., & Wagatsuma, Y. (2019). The effect of comorbidities for the prognosis of community-acquired pneumonia: An epidemiologic study using a hospital surveillance in Japan. BMC Research Notes, 12(1), 1–5. https://doi.org/10.1186/s13104-019-4848-1
Pelton, S. I., Shea, K. M. S., & Weycker, D. (2015). Rethinking Risk for Pneumococcal Disease in Adults: The Role of Risk Stacking. 2(September), 2633851. https://doi.org/10.1093/o
Rello, J. (2007). Importance of appropriate initial antibiotic therapy and de-escalation in the treatment of nosocomial pneumonia. European Respiratory Review, 16(103), 33–39. https://doi.org/10.1183/09059180.00010302
Sridhara, S., Raj, E., Chandra, P., A Ravindra - Authorea, & 2020, U. (2020). Dose Optimization of Antibiotics in Renally Impaired Patients in Indian Settings: A Prospective Observational Study. Authorea.Com, 1–5.
Tambun, S. H., Puspitasari, I., & Laksanawati, I. S. (2019). Evaluasi Luaran Klinis Terapi Antibiotik pada Pasien Community Acquired Pneumonia Anak Rawat Inap. JURNAL MANAJEMEN DAN PELAYANAN FARMASI (Journal of Management and Pharmacy Practice), 9(3), 213. https://doi.org/10.22146/jmpf.47915
Tsoumani, E., Carter, J. A., Salomonsson, S., Stephens, J. M., Tsoumani, E., Carter, J. A., Salomonsson, S., & Stephens, J. M. (2023). Expert Review of Vaccines Clinical , economic , and humanistic burden of community acquired pneumonia in Europe : a systematic literature review Clinical , economic , and humanistic burden of community acquired pneumonia in Europe : a systematic literatur. Expert Review of Vaccines, 22(1), 876–884. https://doi.org/10.1080/14760584.2023.2261785
Viasus, D., Vecino-Moreno, M., De La Hoz, J. M., & Carratalà, J. (2017). Antibiotic stewardship in community-acquired pneumonia. Expert Review of Anti-Infective Therapy, 15(4), 351–359. https://doi.org/10.1080/14787210.2017.1274232
Widiyastuti, A., Kumala, S., R, H. U., & Pratama, A. (2023). Hubungan Rasionalitas Penggunaan Antibiotik terhadap Luaran Klinis Pasien Pneumonia Komunitas Rawat Inap The Relationship between the Rational Use of Antibiotics and the Clinical Outcomes of Community Pneumonia Acquired Patients. 14(1), 109–116.
Published
Issue
Section
License
Copyright (c) 2024 Syahrul Fath Thoriq, Nadia Farhanah Syafhan, Muhammad Luthfi Aziz
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
